Utah People's Post

The Latest News from the Beehive State

Sunday, August 14, 2022
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / Amgen’s Trebananib Fails in Overall Survival Trials

Amgen’s Trebananib Fails in Overall Survival Trials

November 5, 2014 Posted by Contributor

trebananibAmgen Inc. has announced that , its newest experimental ovarian cancer drug, trebananib, has failed in its medical trial stage at improving the survival rate of late-stage ovarian cancer patients.

This anti-tumor treatment drug is designed to be administered together with paclitaxel, a chemotherapy drug. During the study’s Phase 3, doctor’s evaluated both the safety of administration and the efficacy of the drug. Results showed that the drug failed to show the results that Amgen had hoped for. S

Trebananib did not show any statistically significant improvement in survival rates of patients, increasing the overall survival to 19.3 months as compared to the placebo group, which had an overall survival rate of 18.3 months. Obtaining a statistically significant difference was one of the trial’s objective.

Amgen’s TRINOVA-1 trial is one of three late-stage clinical trials attempting to assess the safety and effectiveness of experimental drugs in ovarian cancer patients. Patients taking part in the trial reported several other issues with the drug, especially side effects such as nausea, alopecia end edema.

Despite these issues, Amgen has announced its intention of carrying on with the trials. Executive vice president of Research and Development at Amgen, Sean E. Harper, explained that the company had every intention to go on with its evaluations of trebananib. Amgen intends on evaluating the drug’s efficacy in combinations with other drugs. Harper explained that TRINOVA-1 is just the first phase of a three phase trial and that, although results are disappointing, the trial could continue.

Results obtained during this first phase of the trial will be presented at a medical conference, the company’s vice president of Research and Development said. Later on, the data is also going to be published in a medical journal.

Harper noted that trebananib is still a new substance and that its anti-tumor mechanism needs to be tested in different cancer settings.

In the meantime, the same drug is undergoing clinical trials for its ability of treating kidney, lung, breast and liver cancer.

Statistics show that approximately 14,000 United States women are killed by ovarian cancer yearly, while 21,000 new cases are diagnosed. Sadly, at the time of diagnosis, most patients (70 percent) are in advanced stages of the disease and as such, 80 percent of them succumb to the disease.

Oncologists are reserved about the efficacy of the drug and believe that it will prove to have no benefits in terms of overall survival.

“Thus, FDA approval is unlikely in our view,”

they wrote.

 

 

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: amgen, amgen drug, amgen survival trial, amgen trials, Cancer, ovarian cancer, ovarian cancer dug, ovarian cancer survival, survival rate, trebananib

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

June 29, 2018 By Amelia Donovan

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

June 29, 2018 By Amelia Donovan

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

June 28, 2018 By Amelia Donovan

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

June 27, 2018 By Amelia Donovan

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

June 27, 2018 By Amelia Donovan

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

June 26, 2018 By Amelia Donovan

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

June 25, 2018 By Amelia Donovan

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

June 23, 2018 By Amelia Donovan

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

June 22, 2018 By Amelia Donovan

456 People Dead at U.K. Hospital after Taking too Many Painkillers

June 21, 2018 By Amelia Donovan

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

June 20, 2018 By Amelia Donovan

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

    Jun 29, 2018
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

    Jun 29, 2018
  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

    Jun 27, 2018
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

    Jun 25, 2018
  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

    Jun 22, 2018
  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

    Jun 21, 2018
  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

    Jun 19, 2018
  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

    Jun 18, 2018
  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

    Jun 15, 2018
  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

    Jun 13, 2018

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2022 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact